Therapeutics, Incorporated to Commence Pilot Studies on Hand Sanitizer SAN DIEGO, Feb. 1 /PRNewswire-FirstCall/ -- PURE Bioscience (OTC:PURE) (BULLETIN BOARD: PURE) , a technology based bioscience company, and Therapeutics, Inc., a privately held research and development corporation, today announced the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) by Therapeutics for a hand sanitizer based upon PURE's patented silver dihydrogen citrate (SDC) broad- spectrum antimicrobial. Therapeutics, Inc. submitted the IND in late December 2006 on behalf of the PURE Bioscience/Therapeutics, Inc. collaboration to enable initiation of the first clinical trial of a product containing SDC as an active pharmaceutical ingredient. After reviewing the submission the FDA has determined the product testing in man may begin as proposed. (Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO) "We are pleased to start 2007 with such an important development," stated Michael L. Krall, CEO of PURE Bioscience. The filing of an IND marks a major milestone in our growth plan as we expand beyond our EPA registered hard surface disinfectants to pharmaceutical applications of SDC. After months of development and formulation work with Therapeutics, Inc., we are very gratified to clear this hurdle with the FDA in our efforts to develop and commercialize the first human application for SDC." "Therapeutics looks forward to initiating clinic trials of the hand sanitizer containing SDC. We recognize the potential of this type of product and the benefit it may hold for health care providers and patients," stated Daniel Piacquadio, M.D., CEO of Therapeutics, Inc. PURE and Therapeutics' joint development initiative is intended to capitalize on the pharmaceutical potential of PURE's flagship bioscience technology, an aqueous antimicrobial, silver dihydrogen citrate (SDC). A patented new molecular entity, SDC is an electrolytically generated source of stabilized ionic silver that can serve as the basis for a broad range of products in diverse markets. SDC liquid is colorless, odorless, non-caustic and formulates well with other compounds. PURE granted Therapeutics a license to develop five SDC-based products for the treatment and prevention of dermatological and women's health related bacterial, viral and fungal mediated diseases and conditions. Therapeutics has assumed responsibility for funding and directing the testing and regulatory processes for these selected potential FDA-regulated SDC-based products and anticipates filing four additional product INDs over the next 23 months. About PURE Bioscience PURE Bioscience (PURE) develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. PURE Bioscience, headquartered in El Cajon, California, (San Diego metropolitan area), was incorporated in 1992. For additional information on PURE Bioscience, visit the Company's website: http://www.purebio.com/. About Therapeutics, Incorporated Therapeutics, Incorporated of San Diego, California is a private, internationally recognized research and development corporation dedicated to product success through integration of innovative clinical and regulatory strategies, sound trial design, schedule-driven product development and competitive marketplace analysis. Focusing on new technologies, with an emphasis in topical drug development, Therapeutics, Incorporated manages all aspects of product development from the "bench top" to the physician's office. Therapeutics, Incorporated applies the expertise of seasoned scientists and clinicians to create project specific development plans executed in a milestone-driven project management style. Visit http://www.therapeuticsinc.com/ for more information. This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Investor Contact: Terri MacInnis, Bibicoff & Associates, Inc. 818-379-8500 Media Contact: Karen Sparks, Mentus 858-455-5500 x 275 http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO http://photoarchive.ap.org/ DATASOURCE: PURE Bioscience CONTACT: investors, Terri MacInnis of Bibicoff & Associates, Inc., +1-818-379-8500, ; or media, Karen Sparks of Mentus, +1-858-455-5500, ext. 275, , both for PURE Bioscience Web site: http://www.purebio.com/ http://www.therapeuticsinc.com/

Copyright